The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States.
 
Yichen Zhong
Employment - Merck Sharp & Dome
Stock and Other Ownership Interests - Merck Sharp & Dome
 
Yizhen Lai
Employment - Merck Sharp & Dome
 
Haojie Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Rachael Batteson
Research Funding - Merck (Inst)
 
Yang Meng
Research Funding - Merck (Inst)
 
Tara L. Frenkl
Employment - Amicus Therapeutics (I); Merck; VenatoRx (I)
Leadership - VenatoRx (I)
Stock and Other Ownership Interests - Amicus Therapeutics (I); AstraZeneca (I); GlaxoSmithKline (I); Merck
Travel, Accommodations, Expenses - Amicus Therapeutics (I); Merck; VenatoRx (I)
 
James Luke Godwin
Employment - Merck
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb